At close: September 26 at 3:59 PM EDT
Pre-Market: 6:22 AM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
Operating Cash Flow
-9,452.8080
-7,362.3750
-8,349.4690
-8,067.3590
Investing Cash Flow
-311.9470
-318.2590
-336.7610
-652.2750
Financing Cash Flow
4,277.4820
5,983.9670
4,134.6240
992.8620
End Cash Position
803.0820
1,795.9890
3,492.6560
8,044.2620
Capital Expenditure
-311.9470
-318.2590
-341.0110
-652.2750
Issuance of Capital Stock
4,290.4470
5,991.3590
--
--
Issuance of Debt
--
--
4,350.0000
984.3870
Repayment of Debt
-14.5150
-7.3920
--
--
Free Cash Flow
-9,764.7550
-7,680.6340
-8,690.4800
-8,719.6340
12/31/2021 - 6/16/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SPRC SciSparc Ltd.
0.2409
-2.86%
GRI GRI Bio, Inc.
0.4967
+6.25%
REVB Revelation Biosciences, Inc.
0.8367
+9.93%
ENSC Ensysce Biosciences, Inc.
0.2729
-8.42%
ALLR Allarity Therapeutics, Inc.
2.2300
-2.62%
DRMA Dermata Therapeutics, Inc.
1.5500
0.00%
BPTH Bio-Path Holdings, Inc.
0.9300
+1.86%
ADTX Aditxt, Inc.
0.2195
+1.15%
LIPO Lipella Pharmaceuticals Inc.
0.5078
+12.59%
ZVSA ZyVersa Therapeutics, Inc.
2.3000
+3.14%